Cathepsin B Mouse ELISA Kit (DEIA1417)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

cell culture supernatant, tissues lysates
Species Reactivity
Intended Use
For the quantitative measurement of Mouse Cathepsin B concentrations in tissue lysate cell culture supernatants.
Contents of Kit
1. Recombinant Mouse Cathepsin B Standard (lyophilized): 2 x 10 ng/tube
2. 96-well plate precoated with anti-mouse Cathepsin B antibody: 1
3. Sample diluent buffer: 30 mL
4. Biotinylated anti-mouse Cathepsin B antibody (dilution 1: 100): 130 μL
5. Antibody diluent buffer: 12 mL
6. Avidin-Biotin-Peroxidase Complex (ABC) (dilution 1: 100): 130 μL
7. ABC diluent buffer: 12 mL
8. TMB color developing agent: 10 mL
9. TMB stop solution: 10 mL
Store at 4°C for frequent use, at -20°C for infrequent use. Avoid multiple freeze-thaw cycles.
Detection Range
156 pg/mL-10,000 pg/mL
5 pg/mL
Standard Curve


Have you cited DEIA1417 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Selective Targeting of Tumor and Stromal Cells By a Nanocarrier System Displaying Lipidated Cathepsin B Inhibitor


Authors: Mikhaylov, G.; Klimpel, D.; Schaschke, N.; Mikac, U.; Vizovisek, M.; Fonovic, M.; Turk, V.; Turk, Boris; Vasiljeva, Olga

Cathepsin B (CtsB) is a lysosomal cysteine proteinase that is specifically translocated to the extracellular milieu during cancer progression. The development of a lipidated CtsB inhibitor incorporated into the envelope of a liposomal nanocarrier (LNC-NS-629) is described. Ex vivo and in vivo studies confirmed selective targeting and internalization of LNC-NS-629 by tumor and stromal cells, thus validating CtsB targeting as a highly promising approach to cancer diagnosis and treatment.

Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer


Authors: Bova, GS; MacGrogan, D; Levy, A; Pin, SS; Bookstein, R; Isaacs, WB

Numerous studies have implicated the short arm of chromosome 8 as the site of one or more tumor suppressor genes inactivated in carcinogenesis of the prostate, colon, lung, and liver. Previously, we identified a homozygous deletion on chromosome 8p22 in a metastatic prostate cancer. To map this homozygous deletion physically, long-range restriction mapping was performed using yeast artificial chromosomes (YACs) spanning approximately 2 Mb of chromosome band 8p22. Subcloned genomic DNA and cDNA probes isolated by hybrid capture from these YACs were mapped in relation to one another, reinforcing map integrity. Mapped single-copy probes from the region were then applied to DNA isolated from a metastatic prostate cancer containing a chromosome 8p22 homozygous deletion and indicated that its deletion spans 730-970 kb, Candidate genes PRLTS (PDGF-receptor beta-like tumor suppressor) and CTSB (cathepsin B) are located outside the region of homozygous deletion. Genethon marker D8S549 is located approximately at the center of this region of homozygous deletion. Two new microsatellite polymorphisms, D8S1991 and D8S1992, also located within the region of homozygous deletion on chromosome 8p22, are described. Physical mapping places cosmid CI8-2644 telomeric to MSR (macrophage scavenger receptor), the reverse of a previously published map, altering the interpretation of published deletion studies. This work should prove helpful in the identification of candidate tumor suppressor genes in this region. (C) 1996 Academic Press, Inc.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket